IBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
iBio Inc (IBIO) is not a good buy at the moment for a beginner investor with a long-term strategy. The company is facing significant financial challenges, with no revenue and negative earnings, and the technical indicators suggest a bearish trend. Additionally, there are no strong positive catalysts or proprietary trading signals to support a buy decision.
The MACD is negatively expanding, indicating bearish momentum. RSI is at 22.619, which is in the neutral zone but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading below key support levels, with S1 at 1.619 and S2 at 1.309, suggesting further downside potential.
Analyst coverage from JonesResearch with a Buy rating and a $7 price target, citing the company's extended half-life antibody platform focused on obesity and metabolic indications.
Technical indicators suggest bearish momentum, and there is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q2 2026, revenue dropped to 0 (-100% YoY), net income improved slightly to -$8.99M (+106.07% YoY), and EPS declined to -0.3 (-37.5% YoY). Gross margin remained at 100%, but the lack of revenue is a major concern.
JonesResearch initiated coverage with a Buy rating and a $7 price target, citing the company's focus on obesity and metabolic indications. However, the company is over 12 months away from clinical data, and the stock's movement is expected to be influenced by INHBE siRNA companies.
